Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: A systematic review

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Pratt, Nicole ^a   Roughead, Elizabeth E ^a   Salter, Amy ^b   Ryan, Philip ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antipsychotics; Cerebrovascular events; Death; Hip fracture; Hospitalisation; Pneumonia; Review; Stroke

Indexed keywords

NEUROLEPTIC AGENT;

CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DEMENTIA; DOUBLE BLIND PROCEDURE; HIP FRACTURE; HUMAN; META ANALYSIS (TOPIC); MORTALITY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTIPSYCHOTIC AGENTS; CAUSE OF DEATH; CEREBROVASCULAR DISORDERS; DEMENTIA; DOUBLE-BLIND METHOD; HIP FRACTURES; HUMANS; META-ANALYSIS AS TOPIC; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861936838     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-72     Document Type: Review

References (63)

1. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimers disease. Ballard C, Waite J, Cochrane Database Syst Rev 2006 1 D003476 16437455
2. Haloperidol for agitation in dementia. Lonergan E, Luxenberg J, Colford J, Cochrane Database Syst Rev 2002 2 D002852 12076456
3. Antipsychotics in patients with Alzheimers disease-what is their clinical value? Ballard C, Fossey J, Sharp S, Nat Clin Pract Neurol 2007 3 5 248 249 17389878 (Pubitemid 46745469)
4. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A, Clin Neurol Neurosurg 2005 107 6 497 508 10.1016/j.clineuro.2005.03.013 15922506 (Pubitemid 41395226)
5. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimers disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H, Int J Geriatr Psychiatry 2007 22 5 475 484 10.1002/gps.1792 17471598 (Pubitemid 46831692)
6. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Schneider LS, Dagerman K, Insel PS, Am J Geriatr Psychiatry 2006 14 3 191 210 16505124
7. Effectiveness of atypical antipsychotic drugs in patients with Alzheimers disease. Schneider LS, Tariot PN, Dagerman KS, et al. N Engl J Med 2006 355 15 1525 1538 10.1056/NEJMoa061240 17035647 (Pubitemid 44547805)
8. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. De Deyn PP, Rabheru K, Rasmussen A, et al. Neurology 1999 53 5 946 955 10.1212/WNL.53.5.946 10496251 (Pubitemid 29442108)
9. Olde Rikkert MG. van Iersel MB, Zuidema SU, Koopmans RT, Verhey FR, Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events. Drugs Aging 2005 22 10 845 858
10. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Sacchetti E, Turrina C, Valsecchi P, Drug Saf 2010 33 4 273 288 10.2165/11319120-000000000-00000 20297860
11. Psychotropic medications and the risk of fracture: a meta-analysis. Takkouche B, Montes-Martinez A, Gill SS, Etminan M, Drug Saf 2007 30 2 171 184 10.2165/00002018-200730020-00006 17253881 (Pubitemid 46193066)
12. Antipsychotic drug use and community-acquired pneumonia. Trifiro G, Curr Infect Dis Rep 2011 13 3 262 268 10.1007/s11908-011-0175-y 21394430
13. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Trifiro G, Spina E, Gambassi G, Pharmacol Res 2009 59 1 1 12 10.1016/j.phrs.2008.09.017 18977443
14. Instrumental variable analysis of secondary pharmacoepidemiologic data. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S, Epidemiology 2006 17 4 373 374 10.1097/01.ede.0000222026.42077.ee 16810095 (Pubitemid 44305509)
15. An introduction To instrumental variables for epidemiologists. Greenland S, Int J Epidemiol 2000 29 6 1102 10.1093/oxfordjournals.ije.a019909 11101554
16. Instrumental variables: application and limitations. Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH, Epidemiology 2006 17 3 260 267 10.1097/01.ede.0000215160.88317.cb 16617274
17. Tutorial in biostatistics: the self-controlled case series method. Whitaker HJ, Farrington CP, Spiessens B, Musonda P, Stat Med 2006 25 10 1768 1797 10.1002/sim.2302 16220518
18. Extending an evidence hierarchy to include topics other than treatment: revising the Australian levels of evidence Merlin T, Weston A, Tooher R, BMC Med Res Methodol 2009 9 34 10.1186/1471-2288-9-34 19519887
19. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Schneider LS, Dagerman KS, Insel P, JAMA 2005 294 15 1934 1943 10.1001/jama.294.15.1934 16234500 (Pubitemid 41464695)
20. Mortality in elderly dementia patients treated with risperidone. Haupt M, Cruz-Jentoft A, Jeste D, J Clin Psychopharmacol 2006 26 6 566 570 10.1097/01.jcp.0000239796.21826.39 17110812 (Pubitemid 44772732)
21. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Ballard C, Hanney ML, Theodoulou M, et al. Lancet Neurol 2009 8 2 151 157 10.1016/S1474-4422(08)70295- 3 19138567
22. Antipsychotic drug use and mortality in older adults with dementia. Gill SS, Bronskill SE, Normand SL, et al. Ann Intern Med 2007 146 11 775 786 17548409 (Pubitemid 351650498)
23. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Trifiro G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC, Pharmacoepidemiol Drug Saf 2007 16 5 538 544 10.1002/pds.1334 17036366 (Pubitemid 46824275)
24. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH, Am J Geriatr Psychiatry 2007 15 5 416 424 10.1097/JGP.0b013e31802d0b00 17463191
25. Antipsychotics and the risk of sudden cardiac death. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT, Arch Gen Psychiatry 2001 58 12 1161 1167 10.1001/archpsyc.58.12.1161 11735845 (Pubitemid 33121508)
26. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Kales HC, Valenstein M, Kim HM, et al. Am J Psychiatry 2007 164 10 1568 1576 quiz 1623 10.1176/appi.ajp.2007.06101710 17898349 (Pubitemid 350069737)
27. Antipsychotic medication dispensing and risk of death in veterans and war widows 65years and older. Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R, Am J Geriatr Psychiatry 2007 15 11 932 941 10.1097/JGP. 0b013e31813547ca 17974865
28. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS, Cmaj 2007 176 5 627 632 10.1503/cmaj.061250 17325327 (Pubitemid 46426056)
29. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. Wang PS, Schneeweiss S, Avorn J, et al. N Engl J Med 2005 353 22 2335 2341 10.1056/NEJMoa052827 16319382 (Pubitemid 41713745)
30. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. Liperoti R, Onder G, Landi F, et al. J Clin Psychiatry 2009 70 10 1340 1347 10.4088/JCP.08m04597yel 19906339
31. Antipsychotics and the risk of death in the elderly: an instrumental variable analysis using two preference based instruments. Pratt NL, Roughead EE, Salter A, Ryan P, Pharmacoepidemiol Drug Saf 2010 19 7 699 707 10.1002/pds.1942 20583208
32. Do atypical antipsychotics cause stroke? Herrmann N, Lanctot KL, CNS Drugs 2005 19 2 91 103 10.2165/00023210-200519020-00001 15697324 (Pubitemid 40321762)
33. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. Sacchetti E, Trifiro G, Caputi A, et al. J Psychopharmacol 2008 22 1 39 46 18187531
34. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. Barnett MJ, Wehring H, Perry PJ, J Clin Psychopharmacol 2007 27 6 595 601 10.1097/jcp.0b013e31815a2531 18004126 (Pubitemid 351339446)
35. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Kolanowski A, Fick D, Waller JL, Ahern F, Arch Psychiatr Nurs 2006 20 5 217 225 10.1016/j.apnu.2006.04.004 17010825 (Pubitemid 44436834)
36. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. Liperoti R, Gambassi G, Lapane KL, et al. J Clin Psychiatry 2005 66 9 1090 1096 10.4088/JCP.v66n0901 16187764 (Pubitemid 41442273)
37. Exposure to antipsychotics and risk of stroke: self controlled case series study. Douglas IJ, Smeeth L, BMJ 2008 337 1227 10.1136/bmj.a1227 18755769
38. Risk of hospitalisation for stroke associated with antipsychotic use in the elderly: a self controlled case-series result. Pratt NL, Roughead EE, Ramsay E, Salter A, Ryan P, Drugs Aging 2010 27 11 885 893 10.2165/11584490-000000000- 00000 20964462
39. Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. Percudani M, Barbui C, Fortino I, Tansella M, Petrovich L, J Clin Psychopharmacol 2005 25 5 468 70 10.1097/01.jcp.0000178414.14685.c4 16160623 (Pubitemid 41368370)
40. Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. Sacchetti E, Turrina C, Cesana B, Mazzaglia G, J Psychopharmacol 2010 24 7 1131 2 10.1177/0269881109103202 19304861
41. Risk of cerebrovascular events in elderly users of antipsychotics. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER, J Psychopharmacol 2008
42. Atypical antipsychotics and risk of cerebrovascular accidents. Herrmann N, Mamdani M, Lanctot KL, Am J Psychiatry 2004 161 6 1113 5 10.1176/appi.ajp. 161.6.1113 15169702 (Pubitemid 38736000)
43. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. Gill SS, Rochon PA, Herrmann N, et al. BMJ 2005 330 7489 445 10.1136/bmj.38330.470486.8F 15668211 (Pubitemid 40314208)
44. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L, Int Psychogeriatr 2005 17 4 617 29 10.1017/S1041610205002280 16202186 (Pubitemid 41758766)
45. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. Wang PS, Schneeweiss S, Setoguchi S, et al. J Clin Psychopharmacol 2007 27 6 707 10 10.1097/JCP. 0b013e31815a882b 18004143 (Pubitemid 351339462)
46. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM, BMJ 2005 330 7498 1021 3 10.1136/bmj.330.7498.1021 15860831 (Pubitemid 40604289)
47. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. Liperoti R, Onder G, Lapane KL, et al. J Clin Psychiatry 2007 68 6 929 34 10.4088/JCP.v68n0616 17592919 (Pubitemid 47015494)
48. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F, Osteoporos Int 2009 20 9 1499 506 10.1007/s00198-008-0826-5 19156348
49. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. Jalbert JJ, Eaton CB, Miller SC, Lapane KL, J Am Med Dir Assoc 2010 11 2 120 7 10.1016/j.jamda.2009.10.001 20142067
50. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P, Drug Saf 2011 34 7 567 75 10.2165/11588470-000000000-00000 21663332
51. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J, Am J Psychiatry 2001 158 6 892 8 10.1176/appi.ajp.158.6.892 11384896 (Pubitemid 32547618)
52. Antipsychotic drug use and risk of pneumonia in elderly people. Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC, J Am Geriatr Soc 2008 56 4 661 6 10.1111/j.1532-5415.2007.01625.x 18266664 (Pubitemid 351473519)
53. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Trifiro G, Gambassi G, Sen EF, et al. Ann Intern Med 2010 152 7 418 25 W139-40 20368647
54. Pharmacotherapy and the risk for community-acquired pneumonia. Gau JT, Acharya U, Khan S, Heh V, Mody L, Kao TC, BMC Geriatr 2010 10 45 10.1186/1471-2318-10-45 20604960
55. Risk factors of aspiration pneumonia in Alzheimers disease patients. Wada H, Nakajoh K, Satoh-Nakagawa T, et al. Gerontology 2001 47 5 271 6 10.1159/000052811 11490146 (Pubitemid 32722285)
56. Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. Hollis J, Forrester L, Brodaty H, Touyz S, Cumming R, Grayson D, Aust N Z J Psychiatry 2007 41 9 751 758 10.1080/00048670701519864 17687661 (Pubitemid 47261154)
57. Rothman KJ, Greenland S, Lash TL, Modern epidemiology Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia 3 2008
58. FDA warns antipsychotic drugs may be risky for elderly. Kuehn BM, JAMA 2005 293 20 2462 10.1001/jama.293.20.2462 15914734 (Pubitemid 40705722)
59. Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? Star K, Bate A, Meyboom RH, Edwards IR, Br J Gen Pract 2010 60 579 385 94 10.3399/bjgp10X532396 20883613
60. Randomized, controlled trials, observational studies, and the hierarchy of research designs. Concato J, Shah N, Horwitz RI, N Engl J Med 2000 342 25 1887 92 10.1056/NEJM200006223422507 10861325 (Pubitemid 30419054)
61. Risperidone for psychosis of Alzheimers disease and mixed dementia: results of a double-blind, placebo-controlled trial. Brodaty H, Ames D, Snowdon J, et al. Int J Geriatr Psychiatry 2005 20 12 1153 7 10.1002/gps.1409 16315159 (Pubitemid 43040682)
62. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, Risperidone Study Group. J Clin Psychiatry 1999 60 2 107 15 (Pubitemid 29104387)
63. Clinical symptom responses to atypical antipsychotic medications in Alzheimers disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Sultzer DL, Davis SM, Tariot PN, et al. Am J Psychiatry 2008 165 7 844 54 10.1176/appi.ajp.2008.07111779 18519523 (Pubitemid 351948716)